We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Arcus Biosciences Inc (RCUS) COM USD0.0001

Sell:$27.17 Buy:$27.18 Change: $1.32 (5.10%)
Market closed |  Prices as at close on 12 August 2022 | Switch to live prices |
Change: $1.32 (5.10%)
Market closed |  Prices as at close on 12 August 2022 | Switch to live prices |
Change: $1.32 (5.10%)
Market closed |  Prices as at close on 12 August 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company that is focused on developing cancer therapies. The Company's six investigational products are in the clinical development, with its molecule, an anti-TIGIT antibody, which is in two phase III registrational studies. The Company's differentiated combination therapies are developing to treat multiple large tumor types, including lung, colorectal, prostate and pancreatic cancers. Its clinical development pipeline includes Domvanalimab, AB308, Etrumadenant, Quemliclustat, Zimberelimab and AB521. Domvanalimab is its Fc-silent anti-TIGIT monoclonal antibody. AB308 is its Fc-enabled anti-TIGIT monoclonal antibody. Etrumadenant is designed to inhibit the adenosine-driven impairment of tumor-infiltrating lymphocytes and myeloid cells (dendritic cells, macrophages), mediated by the A2a and A2b receptors. Quemliclustat is an extremely potent and selective small-molecule CD73 inhibitor. Zimberelimab is its anti-PD-1 antibody.

Contact details

3928 Point Eden Way
United States
+1 (510) 6946200

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$1.95 billion
Shares in issue:
72.16 million
New York Stock Exchange
United States
US dollar

Key personnel

  • Terry Rosen
    Chairman of the Board, Chief Executive Officer, Co-Founder
  • Juan Jaen
    President, Co-Founder, Director
  • Robert Goeltz
    Chief Financial Officer, Principal Financial and Accounting Officer
  • Jennifer Jarrett
    Chief Operating Officer, Director
  • Carolyn Tang
    General Counsel
  • Dimitry Nuyten
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.